NCI-TARGET 对体内生理状况之改善

改善慢性肝炎,降低GOT/AST之肝损害指数达60%以上

The NCI/Con A for improving liver function of chronic hepatitis - It reduced more than 60% of abnormal AST/GOT

改善急性肝炎,降低GPT/ALT之肝损害指数达55%以上

The NCI/Con A for improving liver function of acute hepatitis - It reduced more than 55% of abnormal ALT/GPT

改善肾功能,降低64.7%BUN(尿素氮)产生,可降低痛风产生

The NCI/Con A for improving renal (urinary) function - It reduced more than 64.7% of abnormal BUN


提升血小板数量60%以上,降低内出血(如胃溃疡、胃出血及月经出血等)

The NCI/Con A for improving platelets of blood coagulation - It overproduced 60% more of platelets in abnormal bleeding

 

最新消息
2004年NCI-TARGET /Treatment取得美国“抗癌制剂”(Anti-tumor Composition)医学专利。并分别从癌细胞试验及抗癌疗效之动物模式证明具抗癌功效且无毒性(LD50=4000mg),可有效用于临床食用。另外对于肝功能 ( GOT/AST、GPT/ALT指数 )、肾功能( BUN、Creatinine指数及尿酸痛风)、长期胃痛或造血功能(血小板/白血球)及妇科皆具快速改善效果,此为全球独步之医疗技术。
 
NCI-TARGET功效机制
NCI-TARGET对临床表现
对体内生理状况之改善
癌细胞试验结果
适用对象,使用方法
 
c 2010 NCI target | All right reserved